Keep an eye on ‘mini Mesoblast’ CynataFollowing on from Mesoblast’s US approval for its childhood Graft versus Host Disease (GVHD) treatment, Cynata Therapeutics (ASX:CYP) is another stem-cell player to watch as it prepares for imminent trial results.The company is funding its own trials for acute GvHD and diabetic foot ulcers (DFUs) and has partnered programs for osteoarthritis and kidney transplants.Cynata announced the phase I DFU results in early December 2024.The 30-patient trial met its primary objectives of safety and the efficacy measures of wound heling, reduced pain and improved quality of life.The company expects to complete enrolments in the phase II GvHD trial in the current half, with first results in the December half.Results for the first cohort in the phase I/II kidney trial are also due to appear in the current half.Meanwhile, enrolment is complete for the phase III osteoarthritis trial, with results in the June half of 2026.As with Mesoblast, Cynata adopts the allogeneic approach by which donor cells are multiplied and stored for off-the-shelf use (as opposed to using the patient’s own tissue).Cynata is the only clinical-stage company in the world trialing induced pluripotent stem cells (IPSCs), from which the healing agent – mesenchymal stem cells (MSCs) – are derived.IPSCs promise to produce a limitless number of high-quality and high-potency doses from a single donor.Cynata’s stem-cell manufacturing platform, Cymerus, promises to overcome the obstacles of ensuring potency and consistency at scale.GvHD occurs when the transplanted cells recognise the recipient’s cells as ‘foreign’, with the graft attacking the host’s tissues.Only about half of patients respond to the current first-line treatment of corticosteroids.Cynata shares have popped up almost 50% over the last year, but the company’s $50 million is a fraction of Mesoblast’s $4 billion worth.Granted, Cynata is not as far down the track.The company estimates the global addressable market for osteoarthritis at US$11.6 billion, compared with US$9.6 billion for DFUs, US$5.9 billion for kidneys and a relatively modest US$600 million for GvHD.As with a slew of other biotechs, Cynata outlined its progress at this week’s Euroz Hartleys Healthcare Forum in Perth.
https://**promotion blocked**/health/health-check-ahead-of-chemist-warehouse-merger-brokers-ring-the-bell-on-overvalued-sigma-shares/
Keep an eye on ‘mini Mesoblast’ CynataFollowing on from...
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
16.5¢ |
Change
-0.005(2.94%) |
Mkt cap ! $37.28M | |||
| Open | High | Low | Value | Volume |
| 16.5¢ | 17.0¢ | 16.5¢ | $39.66K | 238.2K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 5 | 277684 | 16.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 17.5¢ | 14285 | 1 |
View Market Depth
| Last trade - 16.10pm 16/06/2025 (20 minute delay) ? |
| CYP (ASX) Chart |